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Abstract
Background: Hepatitis C Virus (HCV) genotypes frequency is important for the predication of response to therapy
and duration of treatment. Despite variable response rates experienced in the case of Interferon (IFN) -based
therapies, there was scarcity of data on HCV genotypes frequency in Khyber Pakhtunkhwa (KPK).
Study Design: A total of 200 blood samples were collected from chronic HCV patients prior to the initiation of
anti-viral therapy. The study population included patients from 6 districts of KPK. Active HCV infection was
confirmed in case of all the patients by real time PCR. HCV genotypes were determined in each case by Type-
specific PCR.
Results: The analysis revealed that out of 200 PCR positive samples; 78 (39%) were 2a, 62 (31%) were 3a, 16 (8%)
were 3b, 34 (17%) were untypable while 1a, 2b and 1b were 3 (1.5%), 2 (1%) and 5 (2.5%), respectively.
Conclusion: Genotype determination is not carried out prior to therapy in KPK. Although, the abundantly
prevalent types (2a and 3a) of HCV in KPK are susceptible to combination therapy, yet resistance experienced in
some of the chronic HCV patients may partly be attributed to the prevalence of less prevalent resistant genotypes
(1a, 1b) of HCV among the population.
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Background
Chronic HCV infection frequently progresses to liver
cirrhosis and is associated with an elevated risk for
development of hepatocellular carcinoma [1-3]. Though
symptoms may be mild for decades, 20% of persistently
infected individuals may eventually develop severe liver
disease including cirrhosis and liver cancer [1]. To date
at least six major genotypes of HCV, each having multi-
ple subtypes, have been identified worldwide [2]. The
various HCV genotypes are important with respect to
epidemiology, vaccine development and clinical manage-
ment of chronic HCV infection [3]. HCV genotype has
also been linked with sustained virological response [4].
Some studies have reported that patients with type 2
and type 3 HCV infections are more likely to have a
sustained response to therapy than patients with type 1
H C Vi n f e c t i o n s[ 5 ] .S u s t a i n e dv i r o l o g i c a lr e s p o n s et o
combination therapy in patients infected with HCV-2/3
and HCV-1 genotypes are 65% and 30%, respectively
[6,7]. Therefore, HCV genotype should be determined
prior to therapy.
HCV genotypes 1, 2 and 3 appear to have a worldwide
distribution while subtypes 1a and 1b are the most com-
mon genotypes in the United States [4] and Europe
[8-10]. The most abundant subtype in Japan is subtype
1b [11]. HCV subtypes 2a and 2b are relatively common
i nN o r t hA m e r i c a ,E u r o p ea n dJ a p a na n ds u b t y p e2 ci s
found commonly in northern Italy. HCV genotype 4
appears to be prevalent in North Africa and the Middle
East [12,13] and genotypes 5 and 6 are found in South
Africa and Hong Kong, respectively [14,15]. HCV geno-
types 7, 8 and 9 have been identified only in Vietnamese
patients [16] and genotypes 10 and 11 have been identi-
fied in patients from Indonesia [17]. There is
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HCV isolates should be classified and genotypes 7
through 11 should are regarded by some researchers as
variants of the same group and classified as a single gen-
otype, type 6 [18,19].
In Pakistan, few studies have been conducted in order
to figure out the geographical distribution of various
HCV genotypes [13,20,21]. In Khyber Pakhtunkhwa, the
prevalence of various HCV genotypes is unknown. As
HCV genotypes have earlier been implicated in response
to therapy [4], therefore it was of prime importance to
investigate the frequency distribution of HCV genotypes
in Khyber Pakhtunkhwa province of Pakistan where
genotype determination prior to therapy is not common
practice.
Methodology
Samples were collected from chronically infected
patients with HCV. None of the patients selected for the
study had started with anti-viral therapy. All the patients
duly signed a proforma containing their demographics,
previous history of viral infection etc. Serum was iso-
lated and extraction of RNA was carried out with spin
column based method (Roboscreen extraction kit)
according to the manufacturer’s instructions. HCV-RNA
was amplified using reagents and equipment from the
Cepheid (Cepheid, USA).
HCV genotyping was performed according to the pro-
cedure of Ohno et al., [22]. Briefly, HCV-RNA was
reverse transcribed to cDNA using 100 U of M-MLV
reverse transcriptase at 37°C for 50 minutes. Two µl of
synthesized cDNA was used for subsequent PCR ampli-
fication of 470-bp region from HCV 5’ noncoding
region plus core region by first round PCR. The second
round nested PCR was performed using Type-specific
primers for genotypes 1a, 1b, 1c, 3a, 3c, 4, 2a, 2c, 3b, 5a
and 6a. The final PCR product was electrophorased on a
2% agarose gel to separate type-specific amplified frag-
ments. A 100-bp DNA ladder (Invitrogen, Corp., Cali-
fornia, USA) was run in each gel as DNA size marker
and the HCV genotype for each sample was determined
by identifying the HCV genotype-specific PCR band.
Results
HCV genotype analysis in chronic HCV patients (age
15-60 years) of Khyber Pakhtunkhwa revealed that the
most abundant genotypes/subtypes among the patients
analyzed were 2a followed by subtype 3a (Table 1).
Other common genotypes included the untypable type
of the virus and genotype 3b. Comparatively less com-
mon genotypes were 1b, 1a and 2b (Table 1). Major risk
factors associated with HCV infection were blood trans-
fusion and dental surgery followed by major surgery
(Table 2). The patient’s history indicated that compara-
tively more patients had a history of blood transfusion
in Peshawar and Mardan districts while a history of den-
tal surgery practices was common in less developed dis-
trict Bunir. Moreover, district Bunir and Peshawar had
more cases of a positive family history of HCV infection
as well. In the studied individuals, there were no co-
infections. It was also noted that the overall prevalence
o fc h r o n i cH C Vw a sm o r ei nm a l ea sc o m p a r e dt o
female (Table 2).
Discussion
HCV prevalence is alarmingly high in Pakistan and due
to unsatisfactory health care conditions, the infection is
spreading at a rapid pace [20]. In Khyber Pakhtunkhwa,
where the health care facilities are poorly equipped with
essentials for screening and sterilization, HCV has
become an economic burden over a population with
Table 1 Prevalent HCV genotypes among the Chronic
HCV infected patients of Khyber Pakhtunkhwa.
S.
No
Genotypes Subtypes No of
isolates
%
Frequency
T. No of
isolates
1 2 2a 78 39% 80
2b 2 1%
2 3 3a 62 31% 78
3b 16 8%
3 1 1a 3 1.5% 8
1b 5 2.5%
4 Untypable Untypable 34 17% 34
Total 100 200
Table 2 Demographics of Chronic HCV infected patients.
District Age M/F Ratio Family History
of HCV infection
Co-infection Major surgery Blood transfusion Dental surgery
Bunir 22-56 11/5 5% Nil 2% 5% 9%
Swabi 18-53 13/8 3% = 4% 6% 7%
Dir 16-58 18/12 2% = 3% 5% 8%
Kohat 20-45 16/9 2% = 3% 4% 6%
Mardan 19-56 29/18 3% = 4% 8% 7%
Peshawar 15-60 41/23 4% = 4% 9% 5%
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line.
HCV genotype determination facilitates therapeutic
decisions and strategies [23,24] and it has been reported
that pathogenesis of the disease or response to therapy
may vary according to the type of the virus [9,25]. Gen-
otype determination is not carried out prior to treat-
ment in Khyber Pakhtunkhwa and the treatment
strategies are solely based on qualitative or quantitative
viral detection. Reasons for variable response rates in
the case of different patients for both combination ther-
a p ya n dP e g y l a t e dI F Nc o u l dt h e r e f o r en o tp r o p e r l yb e
sorted out. We attempted to figure out HCV genotypes
prevalent among the population of Khyber Pakhtunkhwa
so as to create awareness among the practitioners about
the importance of the HCV genotype and find a preli-
minary answer to the resistance phenomenon experi-
enced here.
Our study indicated that HCV genotype 2a is the most
abundant followed by 3a and 2b (Table 1). The distribu-
tion of type 2 and 3 is thought to be worldwide [4]
including Pakistan [10]. It has earlier been reported that
HCV 2a and 3a are most susceptible to combination
therapy [5] and good response rates in Khyber Pakh-
tunkhwa may partly be attributed to the most abundant
types of HCV prevalent here. Other types of the virus
including type 1a, 1b and 2b are less prevalent among
the population (Table 1). Genotype 1a and 1b are preva-
lent in the USA [4], Europe [8,9] and Japan [11]. These
genotypes are comparatively less responsive to combina-
tion therapy [5] and the response rates in the case of
Pegylated IFN have been reported to vary from 50-70%
[26]. In Khyber Pakhtunkhwa, it is a common practice
to put the non-responders on prolonged combination
therapy or Pegasys. Resistance in some patients may be
attributed to these less prevalent genotypes among the
population.
HCV genotypes among a considerable number of
chronic HCV patients (17%) could not be determined by
the assay used in this study. Untypeable genotypes have
earlier been reported by other studies conducted in
Pakistan [23]. Sequencing of the untypeable genotypes is
needed not only for academic reasons but also for future
treatment directions.
This study concludes that the most abundant types of
HCV among chronic HCV patients of Khyber Pakh-
tunkhwa province of Pakistan are HCV type 2a, 3a and
3b. Although these abundant types are responsive to
combination therapy and Pegasys, yet proper diagnostic
and treatment strategies should be adopted in order to
minimize the economic burden on the population and
to prevent people from an extra stress of undergoing
successive therapies.
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